Intercept Pharmaceuticals, Inc. announced the appointment of Andrew Saik as Chief Financial Officer. Mr. Saik brings more than 20 years of biopharma finance experience to his new role at Intercept. He was previously Chief Financial Officer of Vyne Therapeutics, where he led a buildout of the company’s finance department in the U.S., renegotiated debt obligations to provide the company with enhanced financial flexibility, and helped raise over $135M to fund operations. Prior to joining Vyne, Mr. Saik held CFO positions at PDS Biotechnology, Inc. (formerly Edge Therapeutics), Vertice Pharma, LLC, and Auxilium Pharmaceuticals, Inc. Prior to Auxilium, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions, Inc., where he helped complete the acquisition of Paladin Labs and restructured $3B of debt into a new corporate structure.